Article
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
Cancer chemotherapy and pharmacology - 1 Sept 2020
Elmeliegy Mohamed, Den Haese Jason, Talati Chetasi, Wetzler Meir, Jusko William J
Abstract excerpt
BACKGROUND: AML patients with FLT3/ITD mutations have poor response to cytarabine-based chemotherapy. FLT3 inhibitors (FLT3i) may resensitize cells to cytarabine (CYT). Improving treatment outcome of this combination may benefit from a mechanistic extrapolation approach from in vitro data. METHOD...
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis
- Benzothiazoles
- Biomarkers, Tumor
- Cell Cycle
- Cell Movement
- Cell Proliferation
- Cytarabine
- Gene Expression Regulation, Neoplastic
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Phenylurea Compounds
- Prognosis
- Survival Rate
- Tumor Cells, Cultured
- fms-Like Tyrosine Kinase 3